These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 11450866)

  • 1. Trends in HCV prevalence among injecting drug users in Glasgow and Edinburgh during the era of needle/syringe exchange.
    Goldberg D; Burns S; Taylor A; Cameron S; Hargreaves D; Hutchinson S
    Scand J Infect Dis; 2001; 33(6):457-61. PubMed ID: 11450866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis C virus antibody prevalence among injecting drug users in Glasgow has fallen but remains high.
    Goldberg D; Cameron S; McMenamin J
    Commun Dis Public Health; 1998 Jun; 1(2):95-7. PubMed ID: 9644121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of hepatitis C virus infection among injecting drug users in Glasgow 1990-1996: are current harm reduction strategies working?
    Taylor A; Goldberg D; Hutchinson S; Cameron S; Gore SM; McMenamin J; Green S; Pithie A; Fox R
    J Infect; 2000 Mar; 40(2):176-83. PubMed ID: 10841096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence rates and risk factors for hepatitis C among drug users not in treatment in Malaysia.
    Vicknasingam B; Narayanan S; Navaratnam V
    Drug Alcohol Rev; 2009 Jul; 28(4):447-54. PubMed ID: 19594801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High hepatitis C virus prevalence and incidence in a community cohort of young heroin injectors in a context of extensive harm reduction programmes.
    Vallejo F; Barrio G; Brugal MT; Pulido J; Toro C; Sordo L; Espelt A; Bravo MJ;
    J Epidemiol Community Health; 2015 Jun; 69(6):599-603. PubMed ID: 25870164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence.
    Turner KM; Hutchinson S; Vickerman P; Hope V; Craine N; Palmateer N; May M; Taylor A; De Angelis D; Cameron S; Parry J; Lyons M; Goldberg D; Allen E; Hickman M
    Addiction; 2011 Nov; 106(11):1978-88. PubMed ID: 21615585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reductions in hepatitis C virus and HIV infections among injecting drug users in New York City, 1990-2001.
    Des Jarlais DC; Perlis T; Arasteh K; Torian LV; Hagan H; Beatrice S; Smith L; Wethers J; Milliken J; Mildvan D; Yancovitz S; Friedman SR
    AIDS; 2005 Oct; 19 Suppl 3():S20-5. PubMed ID: 16251819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis C and its risk management among drug injectors in London: renewing harm reduction in the context of uncertainty.
    Rhodes T; Davis M; Judd A
    Addiction; 2004 May; 99(5):621-33. PubMed ID: 15078237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Performance and image enhancing drug injectors' access to needle syringe programs: Responding to a public policy dilemma.
    van Beek I; Chronister KJ
    Int J Drug Policy; 2015 Sep; 26(9):868-74. PubMed ID: 26118797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Projecting severe sequelae of injection-related hepatitis C virus epidemic in the UK. Part 1: Critical hepatitis C and injector data.
    Bird SM; Goldberg DJ; Hutchinson SJ
    J Epidemiol Biostat; 2001; 6(3):243-65; discussion 279-85. PubMed ID: 11437088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis C prevalence and needle/syringe sharing behaviours in recent onset injecting drug users.
    Robinson GM; Reynolds JN; Robinson BJ
    N Z Med J; 1995 Mar; 108(996):103-5. PubMed ID: 7715873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trends in hepatitis B virus, hepatitis C virus, and human immunodeficiency virus prevalence, risk behaviors, and preventive measures among Seattle injection drug users aged 18-30 years, 1994-2004.
    Burt RD; Hagan H; Garfein RS; Sabin K; Weinbaum C; Thiede H
    J Urban Health; 2007 May; 84(3):436-54. PubMed ID: 17356901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of needle and syringe programs on HIV and HCV transmissions in injecting drug users in Australia: a model-based analysis.
    Kwon JA; Iversen J; Maher L; Law MG; Wilson DP
    J Acquir Immune Defic Syndr; 2009 Aug; 51(4):462-9. PubMed ID: 19387355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of a needle social marketing strategy to control HIV among injecting drug users in China.
    Wu Z; Luo W; Sullivan SG; Rou K; Lin P; Liu W; Ming Z
    AIDS; 2007 Dec; 21 Suppl 8():S115-22. PubMed ID: 18172379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of hepatitis C among injectors in Scotland 1989-2000: declining trends among young injectors halt in the late 1990s.
    Hutchinson SJ; McIntyre PG; Molyneaux P; Cameron S; Burns S; Taylor A; Goldberg DJ
    Epidemiol Infect; 2002 Jun; 128(3):473-7. PubMed ID: 12113492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV, hepatitis B and sexual practices in the street-recruited injecting drug users of Calcutta: risk perception versus observed risks.
    Panda S; Chatterjee A; Bhattacharjee S; Ray B; Saha MK; Bhattacharya SK
    Int J STD AIDS; 1998 Apr; 9(4):214-8. PubMed ID: 9598748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis C and HIV incidence and harm reduction program use in a conflict setting: an observational cohort of injecting drug users in Kabul, Afghanistan.
    Todd CS; Nasir A; Stanekzai MR; Fiekert K; Sipsma HL; Vlahov D; Strathdee SA
    Harm Reduct J; 2015 Oct; 12():22. PubMed ID: 26472126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continued transmission of hepatitis B and C viruses, but no transmission of human immunodeficiency virus among intravenous drug users participating in a syringe/needle exchange program.
    Månsson AS; Moestrup T; Nordenfelt E; Widell A
    Scand J Infect Dis; 2000; 32(3):253-8. PubMed ID: 10879594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. History of syringe sharing in prison and risk of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus infection among injecting drug users in Berlin.
    Stark K; Bienzle U; Vonk R; Guggenmoos-Holzmann I
    Int J Epidemiol; 1997 Dec; 26(6):1359-66. PubMed ID: 9447418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Higher HCV antibody prevalence among Indigenous clients of needle and syringe programs.
    Ward J; Topp L; Iversen J; Wand H; Akre S; Kaldor J; Maher L
    Aust N Z J Public Health; 2011 Oct; 35(5):421-6. PubMed ID: 21973248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.